Haematologic Technologies (HTI), a manufacturer of blood coagulation proteins and reagents, and provider of cGMP, OEM services, reports its ISO 9001:2000 certification
Researchers as well as IVD and pharmaceutical manufacturers in the field of thrombosis and hemostasis can now turn to a familiar face for an enhanced line of products and services.
Achieving ISO status opens a broader menu of products and services to the research, IVD, and pharmaceutical communities, and allows HTI to provide their quality-driven customers with products and services that can be easily incorporated into their own system.
In addition, HTI can now provide greater outsourcing options for OEM manufacturing as well as offer expanded short and long-term stability study services.
Richard Jenny is HTI's president and CEO.
"For the 20 years that HTI has been serving the scientific community, an excellent reputation has been established by providing high quality reagents and services with the goal of achieving the highest level of customer satisfaction," he states.
"Our achievement of becoming an ISO 9001:2000 registered company further illustrates our commitment to quality, continual improvement and customer satisfaction.
"In addition, integrating this achievement with our upgrade to cGMP capabilities enhances our ability to provide an expanded array of services to our IVD and pharma-based customers.
"I am proud of this accomplishment and of the HTI employees who worked diligently as a team to make this event happen.
"Enhancing HTI's quality system to be both ISO and cGMP compliant has resulted in more business, and it seems as if the trend will continue.
"We've already secured two large projects; one being a long-term stability study for a Phase II pharmaceutical and the other being an OEM deal to provide on-board controls for a POC device which is currently on the market.
"From the requests that we get almost weekly, it seems as if further expansion will be in order," Jenny said.
